Table 1 Association of SOX4 expression with the clinicopathological features of 136 patients with PGC

Gender

Male

60

14 (23.3)

9 (15.0)

20 (33.3)

17 (28.3)

NS

Female

76

20 (22.2)

12 (15.8)

25 (32.9)

19 (25.0)

Age

≤ 66 years

65

16 (24.6)

10 (15.4)

21 (32.3)

18 (27.7)

NS

> 66 years

71

18 (25.4)

11 (15.5)

24 (33.8)

18 (25.4)

Tumor size

≤ 2.5 cm

72

19 (26.4)

12 (16.7)

25 (34.7)

16 (22.2)

NS

> 2.5 cm

64

15 (23.4)

9 (14.1)

20 (31.3)

20 (31.3)

Histological grade

G1

18

1 (5.6)

3 (16.7)

4 (22.2)

10 (55.6)

0.02

G2

72

13 (18.1)

3 (4.2)

32 (44.4)

24 (33.3)

G3

33

10 (30.3)

13 (39.4)

8 (24.2)

2 (6.1)

G4

13

10 (76.9)

2 (15.4)

1 (7.7)

0 (0.0)

Pathologic T stage

T1

22

2 (9.1)

2 (9.1)

6 (27.3)

12 (54.5)

0.02

T2

60

4 (6.7)

5 (8.3)

29 (48.3)

22 (36.7)

T3

36

16 (44.4)

10 (27.8)

8 (22.2)

2 (5.6)

T4

18

12 (66.7)

4 (22.2)

2 (11.1)

0 (0.0)

Clinical stage

I

46

4 (8.7)

6 (13.0)

16 (2.2)

20 (43.5)

0.03

II

52

8 (15.4)

4 (7.7)

25 (48.1)

15 (28.8)

III

18

10 (55.6)

5 (27.8)

2 (11.1)

1 (5.6)

IV

20

12(60.0)

6 (30.0)

2 (10.0)

0 (0.0)

Nodal metastasis

Negative

92

12 (13.0)

3 (3.3)

41 (44.6)

36 (39.1)

0.01

Positive

44

22 (50.0)

18 (40.9)

4 (9.1)

0 (0.0)

Distant metastasis

Negative

112

28 (25.0)

16 (14.3)

35 (31.3)

33 (29.5)

NS

Positive

24

6 (25.0)

5 (20.8)

10 (41.7)

3 (12.5)

Venous/lymphatic invasion

Negative

82

22 (26.8)

12 (14.6)

24 (29.3)

24 (29.3)

NS

Positive

54

12 (22.2)

9 (16.7)

21 (38.9)

12 (22.2)

Perineural invasion

Negative

79

20 (25.3)

12 (15.2)

24 (30.4)

23 (29.1)

NS

Positive

57

14 (24.6)

9 (15.8)

21 (36.8)

13 (22.8)